SCHEMBL4091224

SCHEMBL4091224

Fc1ccccc1-c1nc(N2CCCC2)c2c(F)cccc2n1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.71
MAPT P10636 5/20 0.53
ABCB1 P08183 1/20 0.51
SMAD3 P84022 1/20 0.51
LMNA P02545 3/20 0.50
ACP1 P24666 2/20 0.47
TSHR P16473 4/20 0.46
MAPK1 P28482 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HSD17B10 Q99714 2/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
GFER P55789 1/20 0.46
MAOB P27338 1/20 0.44
KMT2A Q03164 2/20 0.44
METAP1 P53582 1/20 0.44
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4099494 0.90 HIF1A (0.65) HIF1AMAPTABCB1SMAD3LMNA
SCHEMBL4084544 0.90 ABCB1 (0.67) HIF1AMAPTABCB1SMAD3LMNA
SCHEMBL1083814 0.84 HIF1A (0.97) HIF1AMAPTABCB1SMAD3LMNA
SCHEMBL1084095 0.83 HIF1A (1.00) HIF1AMAPTABCB1SMAD3LMNA
SCHEMBL4099593 0.83 HIF1A (0.51) HIF1AMAPTLMNATSHRMAPK1
SCHEMBL4753852 0.82 MAPT (0.50) HIF1AMAPTLMNATSHRMAPK1
SCHEMBL1084817 0.82 HIF1A (0.92) HIF1AMAPTABCB1SMAD3LMNA
SCHEMBL4090732 0.79 KMT2A (0.53) HIF1AMAPTLMNATSHRMAPK1
SCHEMBL4090727 0.78 ABCB1 (0.73) HIF1AMAPTABCB1SMAD3LMNA
SCHEMBL1084327 0.77 HIF1A (0.74) HIF1AMAPTABCB1SMAD3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 HIF1A 1496/4885MAPT 4125/4885ABCB1 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.